Appendix B: Sources of evidence considered by the Committee
A. The Evidence Review Group (ERG) report for this appraisal was prepared by School of Health and Related Research (ScHARR), University of Sheffield:
-
Whyte S, Pandor A, Stevenson M, et al., Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer, September 2009
B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.
I) Manufacturer/sponsor:
-
Roche Products
II) Professional/specialist and patient/carer groups:
-
Association of Surgeons of Great Britain and Ireland
-
Cancer Research UK
-
Royal College of Nursing
-
Royal College of Physicians, Medical Oncology Joint Special Committee
-
Beating Bowel Cancer
-
Bowel Cancer UK
-
Macmillan Cancer Support
III) Other consultees:
-
Department of Health
-
NHS Manchester
-
Welsh Assembly Government
IV) Commentator organisations (did not provide written evidence and without the right of appeal):
-
Department of Health, Social Services and Public Safety for Northern Ireland
-
Medicines and Healthcare products Regulatory Agency
-
NHS Quality Improvement Scotland
-
Scottish Medicines Consortium
-
Medac UK
-
Merck Serono
-
Pfizer
-
Roche Products
-
Sanofi-Aventis
-
Institute of Cancer Research
-
MRC Clinical Trials Unit
-
National Institute for Health Research Health Technology Assessment Programme
-
School of Health and Related Research (ScHARR)
-
National Collaborating Centre for Cancer
C. The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer/sponsor consultees and commentators. They gave their expert personal view on bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.
-
Professor Daniel Hochhauser, nominated by the Royal College of Physicians on behalf of NCRI/RCP/RCR/ACP/JCCO – clinical specialist
-
Dr Rob Glynne-Jones, nominated by Bowel Cancer UK – clinical specialist
-
Ian Beaumont (Director of Communications, Bowel Cancer UK), nominated by Bowel Cancer UK
-
Barbara Moss, nominated by Bowel Cancer UK – patient expert
D. Representatives from the following manufacturer/sponsor attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.
-
Roche Products